BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients
October 01, 2021 02:00 ET
|
BioNTech SE
Second Phase 2 trial initiated from BioNTech’s proprietary individualized mRNA-based cancer vaccine platform iNeST Randomized Phase 2 trial will enroll approximately 200 patients with high-risk...
Sunshine Biopharma Opens Twitter Account For Increased Shareholder Engagement
July 27, 2021 09:00 ET
|
Sunshine Biopharma Inc.
MONTREAL, July 27, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral...
Sunshine Biopharma Employs mRNA Vaccine Technology to Expand Its Fight Against Multidrug Resistant Cancer
July 08, 2021 09:00 ET
|
Sunshine Biopharma Inc.
MONTREAL, July 08, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral...
BioNTech gibt Dosierung des ersten Patienten mit fortgeschrittenem Melanom in der Phase-2-Studie mit mRNA-basiertem BNT111 bekannt
June 18, 2021 05:00 ET
|
BioNTech SE
Erstes Programm aus BioNTechs unternehmenseigener mRNA-Krebsimpfstoff-Plattform FixVac schreitet voran, sodass Patienten erstmals in einer randomisierten klinischen Phase-2-Studie behandelt...
BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients with Advanced Melanoma
June 18, 2021 05:00 ET
|
BioNTech SE
First program from BioNTech’s fully-owned mRNA cancer vaccine platform FixVac treats patients in a randomized clinical Phase 2 clinical trial Phase 2 trial is based on positive results from Phase 1...
Beroni Group Signs MoU with tella, Inc to Collaborate in Immunotherapy for Cancer Treatment
May 28, 2021 08:30 ET
|
Beroni Group Limited
NEW YORK and SYDNEY, Australia, May 28, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise today...
Global Peptide Cancer Vaccine Clinical Trials Research Market Outlook 2026
April 22, 2021 10:37 ET
|
KuicK Research
DELHI, India, April 22, 2021 (GLOBE NEWSWIRE) -- “Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026” Report Highlights: Global Peptide Cancer Vaccine Market Trends...
Treos Bio Forms New Subsidiary to Develop a Preventive COVID-19 Peptide Vaccine
June 15, 2020 07:15 ET
|
Treos Bio Corp.
LONDON, June 15, 2020 (GLOBE NEWSWIRE) -- Treos Bio Limited, a clinical stage biopharma company developing targeted peptide cancer immunotherapies, today said that it has developed and successfully...
Treos Bio Reports Positive Final Results of Phase I/II Off-The-Shelf CRC Cancer Immunotherapy in 2020 ASCO Poster Presentation
May 29, 2020 12:17 ET
|
Treos Bio Corp.
LONDON, May 29, 2020 (GLOBE NEWSWIRE) -- Treos Bio Limited, a clinical stage biopharma company developing precision peptide cancer immunotherapies, today presented positive final data from a Phase...
Aldevron Plasmids Used to Support Calviri’s Clinical Trial of a Vaccine Against Canine Cancer
December 03, 2019 09:51 ET
|
Aldevron
TEMPE, A.Z. and FARGO, N.D., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Prevention of cancer onset is the ultimate aspiration for animals and humans. Cancer is caused by mutations that are specific to the...